{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PD-1+inhibitor", "query": { "intervention": "A PD-1 inhibitor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 398, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PD-1+inhibitor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T17:06:58.934Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Cancer", "Recurrent Bladder Carcinoma", "Recurrent Classical Hodgkin Lymphoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Renal Cell Carcinoma", "Stage III Bladder Cancer", "Stage III Lymphoma", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage III Renal Cell Cancer", "Stage III Skin Melanoma", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Skin Melanoma", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Lymphoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Bladder Cancer", "Stage IVB Bladder Cancer", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Enzyme Inhibitor Therapy", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-10-03", "completion_date": "2022-10-30", "has_results": true, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229278" }, { "nct_id": "NCT07423078", "title": "Window of Opportunity in Preserving Laryngeal Function Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Matthew Spector", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2026-04-06", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07423078" }, { "nct_id": "NCT05970497", "title": "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Melanoma Stage III", "Melanoma Stage IV", "Cutaneous Melanoma" ], "interventions": [ { "name": "KB707", "type": "BIOLOGICAL" }, { "name": "Opdualag", "type": "DRUG" }, { "name": "KEYTRUDA ®( Pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Krystal Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2023-10-31", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 15, "location_summary": "Los Angeles, California • Rancho Santa Margarita, California • Weston, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Santa Margarita", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05970497" }, { "nct_id": "NCT04740307", "title": "Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma" ], "interventions": [ { "name": "Pembrolizumab/Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2021-03-16", "completion_date": "2025-07-29", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 7, "location_summary": "Duarte, California • Baltimore, Maryland • New York, New York + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740307" }, { "nct_id": "NCT03644589", "title": "Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Breast Cancer", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-04-01", "completion_date": "2022-10-30", "has_results": false, "last_update_posted_date": "2019-04-26", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03644589" }, { "nct_id": "NCT03153410", "title": "Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX Pancreas Vaccine (GVAX)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "IMC-CS4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-09-27", "completion_date": "2023-08-29", "has_results": true, "last_update_posted_date": "2025-01-09", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03153410" }, { "nct_id": "NCT04248569", "title": "DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fibrolamellar Hepatocellular Carcinoma (FLC)" ], "interventions": [ { "name": "DNAJB1-PRKACA peptide vaccine", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 56, "start_date": "2020-04-20", "completion_date": "2034-03-01", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04248569" }, { "nct_id": "NCT07619313", "title": "AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Locally Advanced Cholangiocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Cholangiocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Ligritinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2026-05-29", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619313" }, { "nct_id": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Splenic Marginal Zone Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Refractory Splenic Marginal Zone Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Richter Syndrome", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-02-19", "completion_date": "2022-01-04", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332980" }, { "nct_id": "NCT05204862", "title": "Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "TU2218", "type": "DRUG" }, { "name": "Anti-PD-1 antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TiumBio Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2021-12-02", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2023-04-03", "last_synced_at": "2026-09-25T17:06:58.934Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05204862" } ] }